Shenzhen Chipscreen Biosciences Co. Ltd. Class ASSE: 688321

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Siglitazone Sodium and Metformin Hydrochloride Extended-Release Tablets

· Issued by Shenzhen Chipscreen Biosciences Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Siglitazone Sodium and Metformin Hydrochloride Extended-Release Tablets

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis